Clinical Immunotherapeutics

, Volume 5, Issue 6, pp 486–489 | Cite as

Anti-D-Rh0 Immunoglobulin

  • Michelle I. Wilde
  • Antona J. Wagstaff
New Drug Profile


  • ▲ Anti-D-Rh0 immunoglobulin (WinRho SD) is the only virally inactivated polyclonal antibody used in preventing the destruction of antibody/platelet complexes in patients with immune thrombocytopenic purpura (ITP)

  • ▲ Its main mechanism of action appears to be via Fc receptor blockade but immunomodulatory mechanisms have also been postulated

  • ▲ Anti-D-Rh0 immunoglobulin achieved response rates ranging from 62 to 92% in children and adults with ITP

  • ▲ In one nonblinded study of children at risk of cerebral haemorrhage, intravenous IgG achieved a greater response than anti-D-Rh0 immunoglobulin as assessed by increases in platelet counts at 72 hours

  • ▲ Increases in platelet counts were greatest in children and in those who had not undergone splenectomy.


Platelet Count Adis International Limited Immune Thrombocytopenic Purpura Drug Profile Intravenous Immune Globulin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bussel JB, Graziano JN, Kimberly RP, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood 1991 May 1; 77: 1884–93PubMedGoogle Scholar
  2. 2.
    Barbolla L, Nieto S, Llamas P, et al. Severe immune haemolytic anaemia caused by intravenous immunoglobulin anti-D in the treatment of autoimmune thrombocytopenia. Vox Sang 1993; 64(3): 184–5PubMedCrossRefGoogle Scholar
  3. 3.
    Univax WinRho SD shows no adverse events, 26 treatment failures in postmarketing data from Canada; launch planned for late May. FDC Rep Pink Sheet 1995 Apr 3: 21–2Google Scholar
  4. 4.
    Andrew M, Blanchette VS, Adams M, et al. A multicentre study of the treatment of childhood chronic idiopathic thrombocytopenic purpura with anti-D. J Pediatr 1992 91A Apr; 120: 522–7PubMedCrossRefGoogle Scholar
  5. 5.
    Yaprak I, Çaǧlayan S, Kansoy S, et al. Long-term use of anti-D in chronic idiopathic thrombocytopenic purpura. Turk J Pediatr 1994 Jan–Mar; 36: 43–7PubMedGoogle Scholar
  6. 6.
    Blanchette V, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994 Sep 10; 344: 703–7PubMedCrossRefGoogle Scholar
  7. 7.
    Krishnamurti L, Charan VD, Desai N, et al. Anti-D immunoglobulin in the treatment of idiopathic thrombocytopenic purpura. Indian J Pediatr 1994 Mar–Apr; 61: 179–82PubMedCrossRefGoogle Scholar
  8. 8.
    Baglin TP, Smith MP, Boughton BJ. Rapid and complete response of immune thrombocytopenic purpura to a single injection of rhesus anti-D immunoglobulin [letter]. Lancet 1986 Jun 7; 1: 1329–30PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Michelle I. Wilde
    • 1
  • Antona J. Wagstaff
    • 1
  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations